Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV-infected cirrhotic patients by 2-D DIGE

Liver International

Volumn 34, Issue 3, 2014, Pages 438-446

  Ferrín, Gustavo ^a,b   Ranchal, Isidora ^a,b   Llamoza, Camilo ^a   Rodríguez Perálvarez, Manuel L ^a   Romero Ruiz, Antonio ^a,c   Aguilar Melero, Patricia ^a   López Cillero, Pedro ^a,b   Briceño, Javier ^a,b   Muntané, Jordi ^a,b   Montero Álvarez, José L ^a,b   De la Mata, Manuel ^a,b  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

Acute phase proteins; Cirrhosis; Early diagnosis of cancer; Liver cancer; Tumour markers

Indexed keywords

BINDING PROTEIN; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C9; FIBRINOGEN; FIBRINOGEN GAMMA; FICOLIN; FICOLIN 3; GALECTIN 3; GALECTIN 3 BINDING PROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN GAMMA 1; SERUM AMYLOID P; UNCLASSIFIED DRUG; VITRONECTIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER PROGRAM; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MIDDLE AGED; POPULATION; PROTEIN EXPRESSION; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; WESTERN BLOTTING; BLOOD; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; COMPLICATION; EARLY DIAGNOSIS; HEPACIVIRUS; LIVER NEOPLASMS; MASS SPECTROMETRY; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; VIROLOGY;

AGED; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; EARLY DIAGNOSIS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTEOMICS; SERUM AMYLOID P-COMPONENT; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL; VITRONECTIN;

EID: 84893757055     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12277     Document Type: Article

References (32)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-73 e1.
3. Lin TY, Lee CS, Chen KM, Chen CC. Role of surgery in the treatment of primary carcinoma of the liver: a 31-year experience. Br J Surg 1987; 74: 839-42.
4. Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138: 493-502.
5. Na K, Lee MJ, Jeong HJ, Kim H, Paik YK. Differential gel-based proteomic approach for cancer biomarker discovery using human plasma. Methods Mol Biol 2012; 854: 223-37.
6. Liang C, Tan GS, Chung MC. 2D DIGE analysis of serum after fractionation by ProteoMiner beads. Methods Mol Biol 2012; 854: 181-94.
7. Rojkind M. Extracellular matrix. In: Arias IM, Jakoby WB, Popper H, Schachter D, Shafritz DA, eds. The Liver Biology and Pathobiology. New York, USA: Raven Press; 1988; 707-716.
8. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54.
9. Jurianz K, Ziegler S, Garcia-Schuler H, et al. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 1999; 36: 929-39.
10. Seiffert D, Geisterfer M, Gauldie J, Young E, Podor TJ. IL-6 stimulates vitronectin gene expression in vivo. J Immunol 1995; 155: 3180-5.
11. Kobayashi J, Yamada S, Kawasaki H. Distribution of vitronectin in plasma and liver tissue: relationship to chronic liver disease. Hepatology 1994; 20: 1412-7.
12. Jaskiewicz K, Chasen MR, Robson SC. Differential expression of extracellular matrix proteins and integrins in hepatocellular carcinoma and chronic liver disease. Anticancer Res 1993; 13: 2229-37.
13. Edwards S, Lalor PF, Tuncer C, Adams DH. Vitronectin in human hepatic tumours contributes to the recruitment of lymphocytes in an alpha v beta3-independent manner. Br J Cancer 2006; 95: 1545-54.
14. Nejjari M, Hafdi Z, Gouysse G, et al. Expression, regulation, and function of alpha V integrins in hepatocellular carcinoma: an in vivo and in vitro study. Hepatology 2002; 36: 418-26.
15. Paradis V, Degos F, Dargere D, et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 2005; 41: 40-7.
16. Hellstern S, Sasaki T, Fauser C, et al. Functional studies on recombinant domains of Mac-2-binding protein. J Biol Chem 2002; 277: 15690-6.
17. Chen R, Tan Y, Wang M, et al. Development of glycoprotein capture-based label-free method for the high-throughput screening of differential glycoproteins in hepatocellular carcinoma. Mol Cell Proteomics 2011; 10: M110 006445.
18. Iacovazzi PA, Trisolini A, Barletta D, et al. Serum 90K/MAC-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: a comparison with alpha-fetoprotein. Clin Chem Lab Med 2001; 39: 961-5.
19. Grassadonia A, Tinari N, Iurisci I, et al. 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J 2004; 19: 551-6.
20. Ait-Goughoulte M, Banerjee A, Meyer K, et al. Hepatitis C virus core protein interacts with fibrinogen-beta and attenuates cytokine stimulated acute-phase response. Hepatology 2010; 51: 1505-13.
21. Dumestre-Perard C, Ponard D, Drouet C, et al. Complement C4 monitoring in the follow-up of chronic hepatitis C treatment. Clin Exp Immunol 2002; 127: 131-6.
22. Murakoshi Y, Honda K, Sasazuki S, et al. Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray. Cancer Sci 2011; 102: 630-8.
23. Okroj M, Hsu YF, Ajona D, Pio R, Blom AM. Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol Immunol 2008; 45: 169-79.
24. Banerjee A, Mazumdar B, Meyer K, et al. Transcriptional repression of C4 complement by hepatitis C virus proteins. J Virol 2011; 85: 4157-66.
25. Biro L, Varga L, Par A, et al. Changes in the acute phase complement component and IL-6 levels in patients with chronic hepatitis C receiving interferon alpha-2b. Immunol Lett 2000; 72: 69-74.
26. Pepys MB, Dash AC, Markham RE, et al. Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol 1978; 32: 119-24.
27. Levo Y, Shalit M, Tur-Kaspa R. Serum amyloid P-component as a marker of liver disease. Am J Gastroenterol 1982; 77: 427-30.
28. Yang MH, Tyan YC, Jong SB, et al. Identification of human hepatocellular carcinoma-related proteins by proteomic approaches. Anal Bioanal Chem 2007; 388: 637-43.
29. Luzzatto G, Schafer AI. The prethrombotic state in cancer. Semin Oncol 1990; 17: 147-59.
30. Zhu WL, Fan BL, Liu DL, Zhu WX. Abnormal expression of fibrinogen gamma (FGG) and plasma level of fibrinogen in patients with hepatocellular carcinoma. Anticancer Res 2009; 29: 2531-4.
31. Liu Y, Zhu X, Zhu J, et al. Identification of differential expression of genes in hepatocellular carcinoma by suppression subtractive hybridization combined cDNA microarray. Oncol Rep 2007; 18: 943-51.
32. Luo JH, Ren B, Keryanov S, et al. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology 2006; 44: 1012-24.